Intrabody and Parkinson's disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1792, Issue 7, 2009, Pages 634-642

  Zhou, Chun ^a   Przedborski, Serge ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

Alpha synuclein; Gene therapy; Gene engineered antibody; Intrabody; LRRK2; Molecular therapy; Parkinson's disease; scFv

Indexed keywords

ALPHA SYNUCLEIN; ALPHA SYNUCLEIN ANTIBODY; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIBODY; ANTINEOPLASTIC AGENT; CENTRAL NERVOUS SYSTEM AGENTS; COMPLEMENTARY DNA; CYCLIN T1 ANTIBODY; EM48 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; GAMMA SYNUCLEIN; IMMUNOGLOBULIN; LEUCINE RICH REPEAT KINASE 2; MESSENGER RNA; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PROTEIN P53 ANTIBODY; RAS PROTEIN ANTIBODY; RECOMBINANT ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY 14; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY 3; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY 6E; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY D10; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY D5; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY F8; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY NAC24; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY NAC3; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY NAC32; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBODY COMBINING SITE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; BINDING AFFINITY; BIOTECHNOLOGY; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SYNTHESIS; FAMILIAL DISEASE; GENE MUTATION; GENETIC ENGINEERING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUNTINGTON CHOREA; IMMUNOGENICITY; MALIGNANT NEOPLASTIC DISEASE; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE; OVARY CANCER; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE;

ALPHA-SYNUCLEIN; ANIMALS; ANTIBODIES; GENE THERAPY; HUMANS; PARKINSON DISEASE; PROTEIN ENGINEERING;

EID: 68649111203     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2008.09.001     Document Type: Review

References (82)

1. Lobato M.N., and Rabbitts T.H. Intracellular antibodies as specific reagents for functional ablation: future therapeutic molecules. Curr. Mol. Med. 4 (2004) 519-528
2. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
3. Braak H., Braak E., Yilmazer D., Schultz C., de Vos R.A., and Jansen E.N. Nigral and extranigral pathology in Parkinson's disease. J. Neural Transm. (Suppl. 46) (1995) 15-31
4. Spillantini M.G., Schmidt M.L., Lee V.M.Y., Trojanowski J.Q., Roos J., and Goedert M. α-Synuclein in Lewy bodies. Nature 388 (1997) 839-840
5. Vila M., and Przedborski S. Genetic clues to the pathogenesis of Parkinson's disease. Nat. Med. 10 Suppl (2004) S58-S62
6. Kohler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (1975) 495-497
7. Miller R.A., Maloney D.G., Warnke R., and Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N. Engl. J. Med. 306 (1982) 517-522
8. von M.M., Adams G.P., and Weiner L.M. Monoclonal antibody therapy for cancer. Annu. Rev. Med. 54 (2003) 343-369
9. Griffiths A.D., Williams S.C., Hartley O., Tomlinson I.M., Waterhouse P., Crosby W.L., Kontermann R.E., Jones P.T., Low N.M., and Allison T.J. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13 (1994) 3245-3260
10. Winter G., Griffiths A.D., Hawkins R.E., and Hoogenboom H.R. Making antibodies by phage display technology. Annu. Rev. Immunol. 12 (1994) 433-455
11. Feldhaus M.J., Siegel R.W., Opresko L.K., Coleman J.R., Feldhaus J.M., Yeung Y.A., Cochran J.R., Heinzelman P., Colby D., Swers J., Graff C., Wiley H.S., and Wittrup K.D. Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat. Biotechnol. 21 (2003) 163-170
12. Hanes J., and Pluckthun A. In vitro selection and evolution of functional proteins by using ribosome display. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 4937-4942
13. Daugherty P.S., Olsen M.J., Iverson B.L., and Georgiou G. Development of an optimized expression system for the screening of antibody libraries displayed on the Escherichia coli surface. Protein Eng. 12 (1999) 613-621
14. Chen G., Hayhurst A., Thomas J.G., Harvey B.R., Iverson B.L., and Georgiou G. Isolation of high-affinity ligand-binding proteins by periplasmic expression with cytometric screening (PECS). Nat. Biotechnol. 19 (2001) 537-542
15. Hudson P.J., and Souriau C. Recombinant antibodies for cancer diagnosis and therapy. Expert. Opin. Biol. Ther. 1 (2001) 845-855
16. Begent R.H., Verhaar M.J., Chester K.A., Casey J.L., Green A.J., Napier M.P., Hope-Stone L.D., Cushen N., Keep P.A., Johnson C.J., Hawkins R.E., Hilson A.J., and Robson L. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat. Med. 2 (1996) 979-984
17. Yazaki P.J., Kassa T., Cheung C.W., Crow D.M., Sherman M.A., Bading J.R., Anderson A.L., Colcher D., and Raubitschek A. Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein. Nucl. Med. Biol. 35 (2008) 151-158
18. Olafsen T., Kenanova V.E., Sundaresan G., Anderson A.L., Crow D., Yazaki P.J., Li L., Press M.F., Gambhir S.S., Williams L.E., Wong J.Y., Raubitschek A.A., Shively J.E., and Wu A.M. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res. 65 (2005) 5907-5916
19. Huston J.S., Levinson D., Mudgett-Hunter M., Tai M.S., Novotny J., Margolies M.N., Ridge R.J., Bruccoleri R.E., Haber E., and Crea R. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 5879-5883
20. Marks J.D., Hoogenboom H.R., Bonnert T.P., McCafferty J., Griffiths A.D., and Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222 (1991) 581-597
21. Adams G.P., and Schier R. Generating improved single-chain Fv molecules for tumor targeting. J. Immunol. Methods 231 (1999) 249-260
22. Wirtz P., and Steipe B. Intrabody construction and expression III: engineering hyperstable V(H) domains. Protein Sci. 8 (1999) 2245-2250
23. Ramm K., Gehrig P., and Pluckthun A. Removal of the conserved disulfide bridges from the scFv fragment of an antibody: effects on folding kinetics and aggregation. J. Mol. Biol. 290 (1999) 535-546
24. Worn A., and Pluckthun A. Stability engineering of antibody single-chain Fv fragments. J. Mol. Biol. 305 (2001) 989-1010
25. Zhou C., Emadi S., Sierks M.R., and Messer A. A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol. Ther. 10 (2004) 1023-1031
26. Lynch S.M., Zhou C., and Messer A. An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. J. Mol. Biol. 377 (2008) 136-147
27. Visintin M., Tse E., Axelson H., Rabbitts T.H., and Cattaneo A. Selection of antibodies for intracellular function using a two-hybrid in vivo system. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 11723-11728
28. Portner-Taliana A., Russell M., Froning K.J., Budworth P.R., Comiskey J.D., and Hoeffler J.P. In vivo selection of single-chain antibodies using a yeast two-hybrid system. J. Immunol. Methods 238 (2000) 161-172
29. De J.G., Fiers E., Eeckhout D., and Depicker A. Analysis of the interaction between single-chain variable fragments and their antigen in a reducing intracellular environment using the two-hybrid system. FEBS Lett. 467 (2000) 316-320
30. Worn A., uf der M.A., Escher D., Honegger A., Barberis A., and Pluckthun A. Correlation between in vitro stability and in vivo performance of anti-GCN4 intrabodies as cytoplasmic inhibitors. J. Biol. Chem. 275 (2000) 2795-2803
31. Carlson J.R. A new means of inducibly inactivating a cellular protein. Mol. Cell Biol. 8 (1988) 2638-2646
32. Bai J., Sui J., Zhu R.Y., Tallarico A.S., Gennari F., Zhang D., and Marasco W.A. Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies. J. Biol. Chem. 278 (2003) 1433-1442
33. Cattaneo A., and Biocca S. The selection of intracellular antibodies. Trends Biotechnol. 17 (1999) 115-121
34. Biocca S., and Cattaneo A. Intracellular immunization: antibody targeting to subcellular compartments. Trends Cell Biol. 5 (1995) 248-252
35. Marasco W.A., Haseltine W.A., and Chen S.Y. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 7889-7893
36. Caron de F.C., Gruel N., Venot C., Debussche L., Conseiller E., Dureuil C., Teillaud J.L., Tocque B., and Bracco L. Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene 18 (1999) 551-557
37. Cochet O., Kenigsberg M., Delumeau I., Virone-Oddos A., Multon M.C., Fridman W.H., Schweighoffer F., Teillaud J.L., and Tocque B. Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression. Cancer Res. 58 (1998) 1170-1176
38. Popkov M., Jendreyko N., McGavern D.B., Rader C., and Barbas III C.F. Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody. Cancer Res. 65 (2005) 972-981
39. Wang C.E., Zhou H., McGuire J.R., Cerullo V., Lee B., Li S.H., and Li X.J. Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J. Cell Biol. 181 (2008) 803-816
40. Deshane J., Siegal G.P., Alvarez R.D., Wang M.H., Feng M., Cabrera G., Liu T., Kay M., and Curiel D.T. Targeted tumor killing via an intracellular antibody against erbB-2. J. Clin. Invest 96 (1995) 2980-2989
41. Alvarez R.D., Barnes M.N., Gomez-Navarro J., Wang M., Strong T.V., Arafat W., Arani R.B., Johnson M.R., Roberts B.L., Siegal G.P., and Curiel D.T. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin. Cancer Res. 6 (2000) 3081-3087
42. Lecerf J.M., Shirley T.L., Zhu Q., Kazantsev A., Amersdorfer P., Housman D.E., Messer A., and Huston J.S. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 4764-4769
43. Colby D.W., Chu Y., Cassady J.P., Duennwald M., Zazulak H., Webster J.M., Messer A., Lindquist S., Ingram V.M., and Wittrup K.D. Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 17616-17621
44. Wolfgang W.J., Miller T.W., Webster J.M., Huston J.S., Thompson L.M., Marsh J.L., and Messer A. Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc. Natl. Acad. Sci. U. S. A 102 (2005) 11563-11568
45. Paganetti P., Calanca V., Galli C., Stefani M., and Molinari M. beta-Site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide. J. Cell Biol. 168 (2005) 863-868
46. Weinreb P.H., Zhen W., Poon A.W., Conway K.A., and Lansbury Jr. P.T. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35 (1996) 13709-13715
47. Eliezer D., Kutluay E., Bussell Jr. R., and Browne G. Conformational properties of alpha-synuclein in its free and lipid-associated states. J. Mol. Biol. 307 (2001) 1061-1073
48. El-Agnaf O.M., Jakes R., Curran M.D., Middleton D., Ingenito R., Bianchi E., Pessi A., Neill D., and Wallace A. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett. 440 (1998) 71-75
49. Conway K.A., Harper J.D., and Lansbury P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4 (1998) 1318-1320
50. Giasson B.I., Uryu K., Trojanowski J.Q., and Lee V.M. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274 (1999) 7619-7622
51. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., and Goedert M. α-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6469-6473
52. Dyson H.J., and Wright P.E. Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell. Biol. 6 (2005) 197-208
53. Uversky V.N. Natively unfolded proteins: a point where biology waits for physics. Protein Sci. 11 (2002) 739-756
54. Emadi S., Liu R., Yuan B., Schulz P., McAllister C., Lyubchenko Y., Messer A., and Sierks M.R. Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry 43 (2004) 2871-2878
55. Barkhordarian H., Emadi S., Schulz P., and Sierks M.R. Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies. Protein Eng. Des. Sel. 19 (2006) 497-502
56. Emadi S., Barkhordarian H., Wang M.S., Schulz P., and Sierks M.R. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J. Mol. Biol. 368 (2007) 1132-1144
57. Maguire-Zeiss K.A., Wang C.I., Yehling E., Sullivan M.A., Short D.W., Su X., Gouzer G., Henricksen L.A., Wuertzer C.A., and Federoff H.J. Identification of human alpha-synuclein specific single chain antibodies. Biochem. Biophys. Res. Commun. 349 (2006) 1198-1205
58. Giasson B.I., Murray I.V., Trojanowski J.Q., and Lee V.M. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem. 276 (2001) 2380-2386
59. Bodles A.M., Guthrie D.J., Greer B., and Irvine G.B. Identification of the region of non-Abeta component (NAC) of Alzheimer's disease amyloid responsible for its aggregation and toxicity. J. Neurochem. 78 (2001) 384-395
60. Davidson W.S., Jonas A., Clayton D.F., and George J.M. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273 (1998) 9443-9449
61. Kim T.D., Paik S.R., and Yang C.H. Structural and functional implications of C-terminal regions of alpha-synuclein. Biochemistry 41 (2002) 13782-13790
62. Braden B.C., Dall'Acqua W., Eisenstein E., Fields B.A., Goldbaum F.A., Malchiodi E.L., Mariuzza R.A., Schwarz F.P., Ysern X., and Poljak R.J. Protein motion and lock and key complementarity in antigen-antibody reactions. Pharm. Acta Helv. 69 (1995) 225-230
63. Outeiro T.F., and Lindquist S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 302 (2003) 1772-1775
64. Tanaka Y., Engelender S., Igarashi S., Rao R.K., Wanner T., Tanzi R.E., Sawa A., Dawson L., Dawson T.M., and Ross C.A. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10 (2001) 919-926
65. Zhou W., Hurlbert M.S., Schaack J., Prasad K.N., and Freed C.R. Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res. 866 (2000) 33-43
66. Giasson B., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q., and Lee V.M. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34 (2002) 521-533
67. Feany M.B., and Bender W.W. A Drosophila model of Parkinson's disease. Nature 404 (2000) 394-398
68. Lakso M., Vartiainen S., Moilanen A.M., Sirvio J., Thomas J.H., Nass R., Blakely R.D., and Wong G. Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J. Neurochem. 86 (2003) 165-172
69. Pavoni E., Flego M., Dupuis M.L., Barca S., Petronzelli F., Anastasi A.M., D'Alessio V., Pelliccia A., Vaccaro P., Monteriu G., Ascione A., De Santis R., Felici F., Cianfriglia M., and Minenkova O., Selection, affinity maturation, and characterization of a human scFv antibody against CEA protein. BMC Cancer 6 (2006) 41
70. Weaver-Feldhaus J.M., Miller K.D., Feldhaus M.J., and Siegel R.W. Directed evolution for the development of conformation-specific affinity reagents using yeast display. Protein Eng. Des. Sel. 18 (2005) 527-536
71. West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A., Dawson V.L., and Dawson T.M. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 16842-16847
72. Smith W.W., Pei Z., Jiang H., Dawson V.L., Dawson T.M., and Ross C.A. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 9 (2006) 1231-1233
73. West A.B., Moore D.J., Choi C., Andrabi S.A., Li X., Dikeman D., Biskup S., Zhang Z., Lim K.L., Dawson V.L., and Dawson T.M. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 16 (2007) 223-232
74. Greggio E., Jain S., Kingsbury A., Bandopadhyay R., Lewis P., Kaganovich A., van der Brug M.P., Beilina A., Blackinton J., Thomas K.J., Ahmad R., Miller D.W., Kesavapany S., Singleton A., Lees A., Harvey R.J., Harvey K., and Cookson M.R. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 23 (2006) 329-341
75. Greggio E., Zambrano I., Kaganovich A., Beilina A., Taymans J.M., Daniels V., Lewis P., Jain S., Ding J., Syed A., Thomas K.J., Baekelandt V., and Cookson M.R. The Parkinson Disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J. Biol. Chem. 283 (2008) 16906-16914
76. Smith W.W., Pei Z., Jiang H., Moore D.J., Liang Y., West A.B., Dawson V.L., Dawson T.M., and Ross C.A. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl Acad. Sci. U. S. A 102 (2005) 18676-18681
77. MacLeod D., Dowman J., Hammond R., Leete T., Inoue K., and Abeliovich A. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52 (2006) 587-593
78. Shin N., Jeong H., Kwon J., Heo H.Y., Kwon J.J., Yun H.J., Kim C.H., Han B.S., Tong Y., Shen J., Hatano T., Hattori N., Kim K.S., Chang S., and Seol W. LRRK2 regulates synaptic vesicle endocytosis. Exp. Cell Res. 314 (2008) 2055-2065
79. Biskup S., Moore D.J., Celsi F., Higashi S., West A.B., Andrabi S.A., Kurkinen K., Yu S.W., Savitt J.M., Waldvogel H.J., Faull R.L., Emson P.C., Torp R., Ottersen O.P., Dawson T.M., and Dawson V.L. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol. 60 (2006) 557-569
80. Hatano T., Kubo S., Imai S., Maeda M., Ishikawa K., Mizuno Y., and Hattori N. Leucine-rich repeat kinase 2 associates with lipid rafts. Hum. Mol. Genet. 16 (2007) 678-690
81. Gandhi P.N., Wang X., Zhu X., Chen S.G., and Wilson-Delfosse A.L. The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J. Neurosci. Res. 86 (2008) 1711-1720
82. Zhou C., Huang Y., Shao Y., May J., Prou D., Perier C., Dauer W., Schon E.A., and Przedborski S. The kinase domain of mitochondrial PINK1 faces the cytoplasm. Proc. Natl. Acad. Sci. U. S. A 105 (2008) 12022-12027